Advanced Medical Iso (ADMD) 0.0018 $ADMD
Advanced Medical Isotope Corporation Provides Commercialization and Strategic Plan Update
ACCESSWIRE - Wed Jun 24, 7:26PM CDT
KENNEWICK, WA / ACCESSWIRE / June 24, 2015 / Advanced Medical Isotope Corporation ("AMIC"
(ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided an update on the Y-90 RadioGel(TM) device de novo submission to the FDA (United States Food and Drug Administration) as well as an update on financial matters.
Are These Trending Sub Penny Stocks On Your May Watchlist?
ACCESSWIRE - Tue May 12, 11:49AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 12, 2015 / The Over The Counter Exchange or "OTC" has thousands of companies, many of which are in the very early stages of development. These stocks trade in all levels of price and when many think of "The OTC" they think penny stocks. The recent trend in 2015 has been focused on those stocks trading below a penny and "yes" they do exist. Companies focused on anything from medical devices to property management have found themselves on this exchange in hopes of raising capital through the public markets. Early this month companies like Hangover Joe's Holding Corp (PINKSHEETS: HJOE), Advanced Medical Isotope Corp. (PINKSHEETS: ADMD) and Enviro-Serv, Inc. (PINKSHEETS: EVSV) have all begun to see increases in volume and share price during the first half of May, 2015.
Advanced Medical Isotope Capital Restructuring Drives Shares Skywards - BrokerBank Securities, Inc.
PR Newswire - Mon May 04, 6:00AM CDT
Advanced Medical Isotope Corp. (OTCBB: ADMD) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, recently announced the initiation of a capital restructuring plan in which $5 million of long term debt was converted into a newly designated series of equity based convertible preferred stock. ADMD believes that these actions will have a positive impact on the Company's balance sheet, potentially eliminating up to $800,000 of convertible debt, potentially eliminating a substantial portion of the warrants outstanding and potentially eliminating a substantial amount of the nearly $11 million of derivative liabilities currently reflected on AMIC's balance sheet.
Advanced Medical Isotope Corporation Provides Additional Update on Strategic Plan
ACCESSWIRE - Thu Apr 30, 2:45PM CDT
KENNEWICK, WA / ACCESSWIRE / April 30, 2015 / Advanced Medical Isotope Corporation ("AMIC" (PINKSHEETS: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided an update on additional matters that will significantly simplify AMIC's capital structure and improve its balance sheet.
Radiopharmaceuticals Market 2015: - Global Strategic Business Report
M2 - Thu Apr 30, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bld7rj/radiopharmaceutica) has announced the addition of the "Radiopharmaceuticals - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 57 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc (US) - Advanced Medical Isotope Corporation (US) - Alliance Medical (UK) - Alseres Pharmaceuticals, Inc (US) - Avid Radiopharmaceuticals (US) - Bayer HealthCare Medical Care (US) - Bracco Diagnostics, Inc. (US) - Cardinal Health, Inc (US) - GE Healthcare (UK) - Ion Beam Applications S.A (Belgium) - Immunomedics, Inc. (US) - Jubilant Pharma (India) - Lantheus Medical Imaging Inc (US) - Mallinckrodt Pharmaceuticals (Ireland) - Medi-Radiopharma Ltd (Hungary) - Nordion, Inc. (Canada) - Peregrine Pharmaceuticals, Inc. (US) - PETNET Solutions Inc (US) - Positron Corporation (US) - Singapore Radiopharmaceuticals Pte Ltd (Singapore) - Triad Isotopes, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS & ISSUES 3. RADIO ISOTOPES MO-99/TC 99 SUPPLIES A REVIEW 4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT 5. IMAGING AGENTS AN OVERVIEW 6. NUCLEAR MEDICINE AN OVERVIEW 7. PRODUCT OVERVIEW 8. PRODUCT INNOVATIONS/INTRODUCTIONS 9. RECENT INDUSTRY ACTIVITY 10. FOCUS ON SELECT PLAYERS 11. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 57 (including Divisions/Subsidiaries 64) - The United States (28) - Canada (2) - Japan (1) - Europe (22) - - France (2) - - Germany (3) - - The United Kingdom (3) - - Italy (2) - - Spain (1) - - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/bl...rmaceutica
IMMU: 2.22 (+0.01), ATNM: 2.44 (+0.07), CAH: 85.01 (+2.00)
Advanced Medical Isotope Corporation Initiates Capital Restructuring Plan
ACCESSWIRE - Thu Apr 23, 5:20AM CDT
KENNEWICK, WA / ACCESSWIRE / April 23, 2015 / Advanced Medical Isotope Corporation ("AMIC" (PINKSHEETS: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided information on completion of the initial steps of the Company's capital restructuring plan.
Penny Stocks Movers for Medican Enterprises, Advanced Medical Isotope, Radiant Creations Group, CIG Wireless, MRI Interventions, and NuGene
PR Newswire - Wed Mar 25, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Medican Enterprises (OTCMKTS:MDCN), Advanced Medical Isotope (OTCMKTS:ADMD), Radiant Creations Group (OTCBB:RCGP), CIG Wireless (OTCBB:CIGW), MRI Interventions (OTCBB:MRIC), and NuGene (OTCBB:NUGN).
Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device
PR Newswire - Tue Dec 23, 10:13AM CST
Advanced Medical Isotope Corporation ("AMIC" (OTCQB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that it has filed a de novo submission with the Food and Drug Administration ("FDA" for marketing clearance for its patented Y-90 RadioGel(TM) device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act (the "Act" .
Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner
ACCESSWIRE - Fri Dec 19, 4:57PM CST
Kennewick, WA / ACCESSWIRE / December 19, 2014 / Advanced Medical Isotope Corporation ("AMIC" (OTCQB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that a Life Sciences Discovery Fund (LSDF) Proof of Concept Grant has been awarded for which AMIC is the commercialization partner. The award was made to Washington State University (WSU) for the proposal titled "Optimized Injectable Radiogels for High-dose Therapy of Non-resectable Solid Tumors," submitted by Principal Investigator Dr. Darrell Fisher, in the amount of $250,000. AMIC will receive a portion of the award by supplying product to WSU for the study as well as providing scientific and technical support. AMIC plans to use the data generated during the study to support the commercialization of the Company's brachytherapy products. Dr. Darrell Fisher serves on the AMIC Medical Advisory Board.
More Fallout From Stock Promotion Scandal
Richard Pearson - Seeking Alpha - Fri Nov 14, 1:35PM CST
Back in March, I highlighted the undisclosed paid stock promotions being run by the Dream Team Group in connection with CytRX (NASDAQ: CYTR ) and Galena (NASDAQ: GALE ). In the wake of that scandal, we have seen both of their stock prices plunge by...
CYTR: 2.82 (+0.22), LBIO: 7.16 (+0.02), GALE: 1.70 (-0.01)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 16.89 (+0.11), MMSI: 23.98 (+0.51)
Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted
PR Newswire - Tue Sep 16, 11:02AM CDT
Advanced Medical Isotope Corporation ("AMIC" (OTCQB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that a patent was awarded for technology related to its brachytherapy products. AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Advanced Medical Isotope Corporation Provides Commercialization and Strategic Plan Update
ACCESSWIRE - Wed Jun 24, 7:26PM CDT
KENNEWICK, WA / ACCESSWIRE / June 24, 2015 / Advanced Medical Isotope Corporation ("AMIC"
(ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided an update on the Y-90 RadioGel(TM) device de novo submission to the FDA (United States Food and Drug Administration) as well as an update on financial matters. Are These Trending Sub Penny Stocks On Your May Watchlist?
ACCESSWIRE - Tue May 12, 11:49AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 12, 2015 / The Over The Counter Exchange or "OTC" has thousands of companies, many of which are in the very early stages of development. These stocks trade in all levels of price and when many think of "The OTC" they think penny stocks. The recent trend in 2015 has been focused on those stocks trading below a penny and "yes" they do exist. Companies focused on anything from medical devices to property management have found themselves on this exchange in hopes of raising capital through the public markets. Early this month companies like Hangover Joe's Holding Corp (PINKSHEETS: HJOE), Advanced Medical Isotope Corp. (PINKSHEETS: ADMD) and Enviro-Serv, Inc. (PINKSHEETS: EVSV) have all begun to see increases in volume and share price during the first half of May, 2015.
Advanced Medical Isotope Capital Restructuring Drives Shares Skywards - BrokerBank Securities, Inc.
PR Newswire - Mon May 04, 6:00AM CDT
Advanced Medical Isotope Corp. (OTCBB: ADMD) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, recently announced the initiation of a capital restructuring plan in which $5 million of long term debt was converted into a newly designated series of equity based convertible preferred stock. ADMD believes that these actions will have a positive impact on the Company's balance sheet, potentially eliminating up to $800,000 of convertible debt, potentially eliminating a substantial portion of the warrants outstanding and potentially eliminating a substantial amount of the nearly $11 million of derivative liabilities currently reflected on AMIC's balance sheet.
Advanced Medical Isotope Corporation Provides Additional Update on Strategic Plan
ACCESSWIRE - Thu Apr 30, 2:45PM CDT
KENNEWICK, WA / ACCESSWIRE / April 30, 2015 / Advanced Medical Isotope Corporation ("AMIC"
(PINKSHEETS: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided an update on additional matters that will significantly simplify AMIC's capital structure and improve its balance sheet. Radiopharmaceuticals Market 2015: - Global Strategic Business Report
M2 - Thu Apr 30, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bld7rj/radiopharmaceutica) has announced the addition of the "Radiopharmaceuticals - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 57 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc (US) - Advanced Medical Isotope Corporation (US) - Alliance Medical (UK) - Alseres Pharmaceuticals, Inc (US) - Avid Radiopharmaceuticals (US) - Bayer HealthCare Medical Care (US) - Bracco Diagnostics, Inc. (US) - Cardinal Health, Inc (US) - GE Healthcare (UK) - Ion Beam Applications S.A (Belgium) - Immunomedics, Inc. (US) - Jubilant Pharma (India) - Lantheus Medical Imaging Inc (US) - Mallinckrodt Pharmaceuticals (Ireland) - Medi-Radiopharma Ltd (Hungary) - Nordion, Inc. (Canada) - Peregrine Pharmaceuticals, Inc. (US) - PETNET Solutions Inc (US) - Positron Corporation (US) - Singapore Radiopharmaceuticals Pte Ltd (Singapore) - Triad Isotopes, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS & ISSUES 3. RADIO ISOTOPES MO-99/TC 99 SUPPLIES A REVIEW 4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT 5. IMAGING AGENTS AN OVERVIEW 6. NUCLEAR MEDICINE AN OVERVIEW 7. PRODUCT OVERVIEW 8. PRODUCT INNOVATIONS/INTRODUCTIONS 9. RECENT INDUSTRY ACTIVITY 10. FOCUS ON SELECT PLAYERS 11. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 57 (including Divisions/Subsidiaries 64) - The United States (28) - Canada (2) - Japan (1) - Europe (22) - - France (2) - - Germany (3) - - The United Kingdom (3) - - Italy (2) - - Spain (1) - - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/bl...rmaceutica
IMMU: 2.22 (+0.01), ATNM: 2.44 (+0.07), CAH: 85.01 (+2.00)
Advanced Medical Isotope Corporation Initiates Capital Restructuring Plan
ACCESSWIRE - Thu Apr 23, 5:20AM CDT
KENNEWICK, WA / ACCESSWIRE / April 23, 2015 / Advanced Medical Isotope Corporation ("AMIC"
(PINKSHEETS: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided information on completion of the initial steps of the Company's capital restructuring plan. Penny Stocks Movers for Medican Enterprises, Advanced Medical Isotope, Radiant Creations Group, CIG Wireless, MRI Interventions, and NuGene
PR Newswire - Wed Mar 25, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Medican Enterprises (OTCMKTS:MDCN), Advanced Medical Isotope (OTCMKTS:ADMD), Radiant Creations Group (OTCBB:RCGP), CIG Wireless (OTCBB:CIGW), MRI Interventions (OTCBB:MRIC), and NuGene (OTCBB:NUGN).
Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device
PR Newswire - Tue Dec 23, 10:13AM CST
Advanced Medical Isotope Corporation ("AMIC"
(OTCQB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that it has filed a de novo submission with the Food and Drug Administration ("FDA" for marketing clearance for its patented Y-90 RadioGel(TM) device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act (the "Act" . Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner
ACCESSWIRE - Fri Dec 19, 4:57PM CST
Kennewick, WA / ACCESSWIRE / December 19, 2014 / Advanced Medical Isotope Corporation ("AMIC"
(OTCQB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that a Life Sciences Discovery Fund (LSDF) Proof of Concept Grant has been awarded for which AMIC is the commercialization partner. The award was made to Washington State University (WSU) for the proposal titled "Optimized Injectable Radiogels for High-dose Therapy of Non-resectable Solid Tumors," submitted by Principal Investigator Dr. Darrell Fisher, in the amount of $250,000. AMIC will receive a portion of the award by supplying product to WSU for the study as well as providing scientific and technical support. AMIC plans to use the data generated during the study to support the commercialization of the Company's brachytherapy products. Dr. Darrell Fisher serves on the AMIC Medical Advisory Board. More Fallout From Stock Promotion Scandal
Richard Pearson - Seeking Alpha - Fri Nov 14, 1:35PM CST
Back in March, I highlighted the undisclosed paid stock promotions being run by the Dream Team Group in connection with CytRX (NASDAQ: CYTR ) and Galena (NASDAQ: GALE ). In the wake of that scandal, we have seen both of their stock prices plunge by...
CYTR: 2.82 (+0.22), LBIO: 7.16 (+0.02), GALE: 1.70 (-0.01)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 16.89 (+0.11), MMSI: 23.98 (+0.51)
Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted
PR Newswire - Tue Sep 16, 11:02AM CDT
Advanced Medical Isotope Corporation ("AMIC"
(OTCQB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that a patent was awarded for technology related to its brachytherapy products. AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy. 
